Key takeaways
- Neither WADA’s 2026 Prohibited List nor the 2027 List, in force from 1 January 2027, names retatrutide or its development code, LY3437943 (full-text search, 18 Nov 2026). WADA says a peptide not named on the List “may still be prohibited”.
- Class S0 prohibits at all times any pharmacological substance not addressed elsewhere on the List and with “no current approval by any governmental regulatory health authority for human therapeutic use”, such as “drugs under pre-clinical or clinical development”.
- Retatrutide is investigational and approved nowhere: the TGA says it has not been approved “by the TGA or any comparable international regulator”. We draw no S0 conclusion; WADA and anti-doping organisations apply the List.
- Sport Integrity Australia’s retatrutide page says it “is not listed on the Prohibited List”, a statement about the List’s names; WADA says an unnamed peptide “may still be prohibited”, and the same SIA page warns that counterfeit peptides may be contaminated with prohibited substances.
- WADA’s 2026 and 2027 Monitoring Programs, which cover substances not on the List, name semaglutide and tirzepatide. They do not name retatrutide.
01Is retatrutide on the WADA Prohibited List?
It is not named. We searched the full text of the World Anti-Doping Agency’s 2026 Prohibited List, and of the 2027 List that takes effect on 1 January 2027, for “retatrutide”, for its development code “LY3437943”, and for the receptor terms “glucagon”, “GLP” and “GIP”. None appears, in any class or in either index (18 November 2026). Both Lists do name BPC-157, as an example in class S0.
“Not named” is all the List itself says about retatrutide. The List is not a closed index: S0 says it covers many substances “including but not limited to” the ones it names, and it is defined by approval status rather than by names. How a substance the List does not name is treated is decided by WADA and by anti-doping organisations. We do not make that call here.
02What does class S0 say?
S0, “non-approved substances”, opens the List. It is prohibited at all times, in and out of competition, and “All prohibited substances in this class are Specified Substances.” The 2026 text reads:
“Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.”
The 2027 List keeps that sentence and adds “peptides” to its examples. WADA’s explanatory note for 2027 says: “Many peptides, not approved for human use by regulatory authorities, fulfill the criteria of the World Anti-Doping Code for inclusion on the Prohibited List and fall under the S0 (Non-Approved Substances) class, or other classes (such as S2 or S4). Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
| List | In force | Retatrutide | S0 examples |
|---|---|---|---|
| 2026 | 1 Jan 2026 | Not named; WADA’s 2027 notes say an unnamed peptide “may still be prohibited” | Drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use |
| 2027 | 1 Jan 2027 | Not named; WADA’s 2027 notes say an unnamed peptide “may still be prohibited” | The same, plus “peptides” |
Retatrutide is a single peptide that activates the receptors for three hormones. Whether the general sentences above reach it is a question this page leaves to anti-doping organisations.
03What is retatrutide’s approval status?
S0 turns on approval for human therapeutic use, so approval status matters. These are regulators’ own words, dated.
| Regulator | Date | What it says about retatrutide |
|---|---|---|
| FDA, United States | Page current as of 1 Oct 2026 | Not a component of any FDA-approved drug; has “not been found safe and effective for any condition” |
| MHRA, United Kingdom | 15 Oct 2026 | “Retatrutide has not been authorised for use in the UK.” |
| TGA, Australia | 5 Nov 2026 | “Still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator” |
Retatrutide is an investigational Eli Lilly drug, approved nowhere. What its trials measured is in our retatrutide research guide.
We set the List’s words and the regulators’ words side by side and stop there. Applying S0 to a substance the List does not name is for WADA and anti-doping organisations. Sport Integrity Australia’s page on retatrutide, below, does not describe it as an S0 substance.
04What have anti-doping bodies said about retatrutide?
Dated statements we found that name retatrutide, with the WADA Lists and Monitoring Programs, checked on 18 November 2026.
| Date | Who | What it says |
|---|---|---|
| 1 Jan 2026 | WADA | 2026 List in force; retatrutide not named. The 2026 Monitoring Program lists “Markers of Semaglutide and Tirzepatide” |
| By 8 Jun 2026 | Sport Integrity Australia | Retatrutide page, earliest archived copy: under the 2026 List, “Retatrutide is not listed on the Prohibited List” |
| 21 Sep 2026 | WADA | Publishes the 2027 List and its explanatory notes, which say an unnamed peptide “may still be prohibited”; says the status of GLP-1 receptor agonists, “including semaglutide and tirzepatide, will remain unchanged for 2027”. Retatrutide not named |
| 22 Oct 2026 | Sport Integrity Australia | Newest archived copy of the retatrutide page; wording unchanged |
| 5 Nov 2026 | Sport Integrity Australia | Newest archived copy of its peptides page: products containing retatrutide, GHK-Cu or melanotan II given as examples of unapproved peptide products, meaning goods not on Australia’s register of therapeutic goods |
| 1 Jan 2027 | WADA | 2027 List takes effect. The 2027 Monitoring Program lists “GLP-1 Agonists” as “Semaglutide and tirzepatide”; retatrutide not named |
Sport Integrity Australia names retatrutide on two pages. Its retatrutide page says the drug is “currently not approved for therapeutic use by the TGA or any other international regulatory agency”, that counterfeit peptides, “including retatrutide, are being sold online illegally”, and that “there is also a possibility that these peptides are contaminated with prohibited substances, which could result in athletes committing an Anti-Doping Rule Violation (ADRV).” Its peptides page defines unapproved peptide products as goods not included in the Australian Register of Therapeutic Goods and says they “can also be illegal and/or prohibited for use in sport”. We read both pages on the Internet Archive, because the live site did not respond to our tools.
WADA has not named retatrutide. Its September 2026 statement says the status of GLP-1 receptor agonists, “including semaglutide and tirzepatide”, will remain unchanged for 2027, and calls them substances “now widely used in society”. It names those two approved prescription medicines and does not mention retatrutide or class S0.
05Who decides, and what does the Code say?
WADA sets the List. Under the World Anti-Doping Code (Article 4.3.3, worded the same in the 2021 edition now in force and in the 2027 edition that takes effect on 1 January 2027), WADA’s determination of the substances on the List and of their classification “is final and shall not be subject to any challenge by an Athlete or other Person”.
Anti-doping organisations apply it. National bodies such as Sport Integrity Australia publish guidance on named substances, and the athlete’s own organisation is the one to ask about a specific product.
The athlete is responsible. Article 2.1.1, the same in both editions: “It is the Athletes’ personal duty to ensure that no Prohibited Substance enters their bodies.” Athletes are responsible for any prohibited substance found in their samples, and the Code says intent, fault, negligence or knowing use do not need to be shown.
Monitoring is not prohibition. The Monitoring Program covers, in the Code’s words quoted on it, “substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport.” More on how the List treats peptides: peptides and anti-doping.
06What we don’t know
- How WADA or a national anti-doping organisation would classify retatrutide. We found no published decision on it.
- Whether WADA’s September 2026 statement on GLP-1 receptor agonists has any bearing on retatrutide. It names only semaglutide and tirzepatide.
- What UK Anti-Doping and USADA say. Their sites blocked our tools, and web searches on 18 November 2026 found no statement from either that names retatrutide.
- Whether the List will name retatrutide in future. WADA revises it every year.
- What Global DRO returns for retatrutide. Its search does not work with our tools, so we have not checked it.
The legal position by market: UK, Australia and US. Status changes are logged in our regulatory tracker.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice, and athletes should check with their national anti-doping organisation.